Our Commitment to Sustainability
A Baseline for Excellence
Simtra BioPharma Solutions is a premier diversified contract development and manufacturing organization (CDMO). Our footprint is global, matching our clients’ needs, with operations spanning two state-of-the-art facilities in the United States and Germany. We provide our customers with 65+ years of combined experience inherited from our Baxter legacy.
Established as a standalone entity in 2023, we are at the start of a transformative journey, with the opportunity to build out a thoughtful program designed for our business, people and communities. Sustainability has been top of mind in guiding the way we do business and will be critical in how we increase our footprint going forward. We are committed to leveraging our long-standing operational practices with a new lens on managing our environmental impact, finding more ways to benefit our communities and bolstering our governance practices.
We are fortified by strategic backing from Warburg Pincus and Advent International, who will provide valuable input into our overall sustainability strategy. Both firms are active members of Principles for Responsible Investment (PRI) and Sustainable Markets Initiative.
The 2023 Simtra Sustainability Fact Sheet
To officially launch our sustainability efforts, we have compiled an initial summary. The 2023 Simtra Sustainability Fact Sheet is focused on setting our baseline for excellence, emphasizing how environmental, social and governance (ESG) indicators influence all that we do. We will move beyond benchmarking in 2024, standing up a dedicated program and publishing a comprehensive report on our progress in early 2025.
Meet the ESG Committee
Our sustainability commitments are led by a diverse group of senior executive leaders who span Regulatory & Quality, Human Resources, Legal, Risk & Integrity, Marketing and Operations. The Steering Committee was established soon after the company’s formation in December 2023 both to support ongoing endeavors and to pioneer long-term strategies.